TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01627236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: methylprednisolone 1mg/kg intravenous drip qd，for 3 days glucocorticoid
Study: NCT02656940

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 1 - diet rich in n-3 and n-6 PUFA
Description: In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 2 - diet rich in MUFA
Description: In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 3 - Placebo group
Description: Placebo group was instructed to keep their eating habits and consuming placebo for 60 days.
Study: NCT02698462

Intervention type: OTHER
Group type: OTHER
Intervention: Family history questionnaire
Description: All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
Study: NCT03682536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days
Study: NCT03613610

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radio-frequency ablation of genicular nerves
Description: Ablation of the genicular nerves for pain relief in advanced knee osteoarthritis

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radio-frequency ablation of genicular nerves
Description: Ablation of the genicular nerves for pain relief in advanced knee osteoarthritis
Study: NCT03927807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.~Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.~Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.~Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.~Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity.
Study: NCT02947412

Intervention type: OTHER
Intervention: laparoscopic sleeve gastrectomy
Description: laparoscopic sleeve gastrectomy
Study: NCT00815243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Description: Standard synchronous or asynchronous telemedicine consultations according recommendations and best practice models of ISfTeH

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment plan
Description: Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment plan
Description: Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
Study: NCT02838953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Comprehensive intervention based on a thorough patient assessment followed by patient- tailored therapies that include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.
Study: NCT03937791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 T Cell Receptor (TCR)
Description: One dose of E7 TCR T cells (1x10\^11 cells) will be administered intravenously over 20 to 30 minutes.
Study: NCT00815243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment plan
Description: Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
Study: NCT00666874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle changes
Description: Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - general information
Description: General information about healthy food choices and exercise
Study: NCT00135733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amevive (Alefacept)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01514500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: Administered s.c. (subcutaneously, under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: Administered s.c. (subcutaneously, under the skin)
Study: NCT03682536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: Specified dose on specified days
Study: NCT01514500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (somapacitan)
Description: Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)
Study: NCT04688411

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MED-Go App
Description: A novel multifunctional mobile app (MED-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
Study: NCT03456063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab will be administered as intravenous (IV) infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle (every 3 weeks) for 4 cycles during the neoadjuvant treatment phase~Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) every 3 weeks for 16 cycles during the post-operative adjuvant phase
Study: NCT02516254

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified bread
Description: 50 g of fortified bread + placebo daily
Study: NCT03456063

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/m\^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
Study: NCT02516254

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplement
Description: vitamin D supplement+ plain bread

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: plain bread+placebo
Study: NCT03456063

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/m\^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study: NCT04160728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Work/ rest scenario
Description: For every hour of work, the participants were asked to take 3-10 minutes break in the shade.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydration scenario
Description: Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work
Study: NCT03456063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study: NCT04160728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clothing scenario
Description: Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-carts scenario
Description: Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)
Study: NCT03456063

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m\^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m\^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study: NCT04160728

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Business as usual scenario
Description: No interference with the usual work day of the participants

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham evaluation
Description: Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment
Study: NCT05605431

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: over nightSleep study

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: over nightSleep study
Study: NCT04047641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given Intravenous
Study: NCT03354975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential Training
Description: Participants in the experiential training will be provided with information about using exposure therapy to treat patients with anxiety via lecture-style teaching. Then, they will themselves undergo a one-session phobia treatment for spiders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training-As-Usual
Description: The training-as-usual condition will incorporate passive and active learning components. The first half of the training will include lecture-style teaching about using exposure therapy to treat patients with anxiety. The second half of training will incorporate active learning components (e.g., role plays) to reinforce concepts discussed in the first half of training.
Study: NCT01845883

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Deep Brain Stimulation (DBS)
Description: Patients with DBS will participate to the study both when the stimulation is off and on.
Study: NCT04559919

Intervention type: OTHER
Intervention: Seizure status
Description: We will collect information on first seizure ever, last seizure ever, number of seizure in last two months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tests
Description: We will collect results from imaging, electroencephalogram, and laboratory tests.

Intervention type: OTHER
Intervention: Epilepsy
Description: We will collect information on risk factors of epilepsy, cause of epilepsy, epilepsy type/syndrome, medications tried, if the epilepsy is drug resistent, side effects of antiepileptic drugs.

Intervention type: OTHER
Intervention: Demographics and psychosocial
Description: We will collect information on age, sex, date of death if applicable, marital status, education level, income type, driving status, employment, benefits, sick leave, number of household members.

Intervention type: OTHER
Intervention: Health care
Description: We will collect information on received health care; visit dates, caregiver, dispensation dates of antiepileptic drugs
Study: NCT04515927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS002
Description: Biological: JS002 Administered by subcutaneous injection
Study: NCT01699932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride+metformin (Amaryl M®) - HOE4900
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT01224665

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Patients undergo radical cystectomy
Study: NCT04047641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given by mouth
Study: NCT01224665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo radical cystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic standard lymphadenectomy
Description: Patients undergo standard pelvic lymphadenectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic extended lymphadenectomy
Description: Patients undergo extended pelvic lymphadenectomy
Study: NCT04557449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor
Study: NCT03388437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NI-NAVA
Description: Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation
Study: NCT02738216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal Yoga
Description: As part of the yoga program, participants will be asked to go to one 75-minute prenatal yoga class each week for 9 weeks. The yoga classes will be designed to be safe for pregnant women. In addition to classes, the yoga teacher will ask them to practice yoga at home during the program. Each participant will be given a yoga mat and a prenatal yoga DVD to take home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mother Baby Wellness
Description: This workshop is aimed at promoting moms' and babies' good health and will involve attending one 75-minute class each week for 9 weeks. Classes will cover topics such as: child development in the first year, child eating and sleeping in the first year, maintaining good health as a mom of an infant, and recent advances in women's healthcare. In addition to classes, participants will be given materials to review/ read at home.
Study: NCT01969864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRSA Video Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PI Video Intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CDC Health Website Intervention
Study: NCT00570128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil HCl
Description: Blinded donepezil 2.5 milligram per day (mg/day) (2.5 milliliter per day \[mL/day\]) orally for participants with body weight (BW) 20 and less than (\<) 25 kilogram (kg), 5 mg/day (5 mL/day) orally for participants with BW 25 to \<50 kg, and 10 mg/day (10 mL/day) orally for participants with BW greater than or equal to (\>=) 50 kg liquid formulation (1 milligram per 1 milliliter \[1 mg/1 mL\]) (titrated to 0.1 to 0.2 milligram per kilogram per day \[mg/kg/day\] based on BW).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid formulation matched to active treatment for oral administration.
Study: NCT02906917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart
Description: Administered subcutaneously (s.c. under the skin) once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Administered subcutaneously (s.c. under the skin) once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Administered subcutaneously (s.c. under the skin) once daily.
Study: NCT03470116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy with Mac Grath
Description: Patients of this group will benefit MacGrath MAC video laryngoscopy for intubation after curarization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct laryngoscopy
Description: Patients of this group will benefit direct laryngoscopy for intubation after curarization
Study: NCT02132624

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous 3rd generation CD19-targeting CAR T cells
Description: Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
Study: NCT01613937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dulce Mother lifestyle training program
Description: 12 once weekly culturally tailored lifestyle management sessions
Study: NCT02625337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood taking
Description: Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.